JP3282130B2 - ホメオボックス・ペプチドを含む新規な神経親和性成長因子 - Google Patents

ホメオボックス・ペプチドを含む新規な神経親和性成長因子

Info

Publication number
JP3282130B2
JP3282130B2 JP51035391A JP51035391A JP3282130B2 JP 3282130 B2 JP3282130 B2 JP 3282130B2 JP 51035391 A JP51035391 A JP 51035391A JP 51035391 A JP51035391 A JP 51035391A JP 3282130 B2 JP3282130 B2 JP 3282130B2
Authority
JP
Japan
Prior art keywords
peptide
homeobox
sequence
homeobox peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51035391A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05502885A (ja
Inventor
ジョリオ，アラン
プロシアンツ，アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JPH05502885A publication Critical patent/JPH05502885A/ja
Application granted granted Critical
Publication of JP3282130B2 publication Critical patent/JP3282130B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP51035391A 1990-06-05 1991-06-05 ホメオボックス・ペプチドを含む新規な神経親和性成長因子 Expired - Lifetime JP3282130B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR90/06912 1990-06-05
FR9006912A FR2662698A1 (fr) 1990-06-05 1990-06-05 Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.

Publications (2)

Publication Number Publication Date
JPH05502885A JPH05502885A (ja) 1993-05-20
JP3282130B2 true JP3282130B2 (ja) 2002-05-13

Family

ID=9397246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51035391A Expired - Lifetime JP3282130B2 (ja) 1990-06-05 1991-06-05 ホメオボックス・ペプチドを含む新規な神経親和性成長因子

Country Status (9)

Country Link
EP (1) EP0485578B1 (enExample)
JP (1) JP3282130B2 (enExample)
AT (1) ATE143691T1 (enExample)
BR (1) BR9105783A (enExample)
DE (1) DE69122472T2 (enExample)
FR (1) FR2662698A1 (enExample)
IE (1) IE911914A1 (enExample)
PT (1) PT97877A (enExample)
WO (1) WO1991018981A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192312A (en) * 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
FR2682875A1 (fr) * 1991-10-24 1993-04-30 Fidia France Sarl Utilisation de l'acide polysialique alpha2-8 pour la regulation de l'action des peptides homeoboites.
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
WO1997042222A1 (en) * 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6800286B1 (en) 1998-08-19 2004-10-05 The Regents Of The University Of Colorado Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
CA2350919A1 (en) 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
FR2810046B1 (fr) * 2000-06-07 2004-09-10 Neurotech Procede d'immortalisation conditionnelle de cellules et les constructions proteiques pour sa mise en oeuvre
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
FR2897780B1 (fr) * 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20100266592A1 (en) 2009-04-14 2010-10-21 Trojan Technologies, Ltd. Therapeutic antennapedia-antibody molecules and methods of use thereof
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
EP3960195B1 (en) * 2015-09-23 2025-01-08 Centre national de la recherche scientifique Engrailed for treatment of amyotrophic lateral sclerosis
JP2026503094A (ja) 2023-01-13 2026-01-27 ブレインエバー 安定化エングレイルドタンパク質水性組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system

Also Published As

Publication number Publication date
WO1991018981A3 (fr) 1992-03-19
DE69122472D1 (de) 1996-11-07
ATE143691T1 (de) 1996-10-15
WO1991018981A2 (fr) 1991-12-12
JPH05502885A (ja) 1993-05-20
FR2662698A1 (fr) 1991-12-06
EP0485578A1 (fr) 1992-05-20
PT97877A (pt) 1992-04-30
DE69122472T2 (de) 1997-04-17
BR9105783A (pt) 1992-07-21
IE911914A1 (en) 1991-12-18
FR2662698B1 (enExample) 1995-03-24
EP0485578B1 (fr) 1996-10-02

Similar Documents

Publication Publication Date Title
JP3282130B2 (ja) ホメオボックス・ペプチドを含む新規な神経親和性成長因子
US5888762A (en) Neurotropic growth factors comprising a homeobox peptide
Joliot et al. Antennapedia homeobox peptide regulates neural morphogenesis.
US8603967B2 (en) Carrier peptide fragment and use thereof
KR100242093B1 (ko) 신경교 유도 신경 영양성 인자
KR100253762B1 (ko) Bdnf 및 nt-3 의 폴리에틸렌 글리콜 유도체
EP2213296B1 (en) Fgf1/fgf2 chimeric protein and uses thereof
US7205387B2 (en) Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US5670481A (en) Dorsal tissue affecting factor (noggin) and compositions comprising same
JPH06500016A (ja) キメラ神経栄養因子
CA2185671A1 (en) Heparin-binding growth factors for gene therapy and anterior eye disorders
US6511823B1 (en) Heparin binding neurotrophic factor gene sequence
JP2003525591A (ja) 神経組織の成長の誘導および生存の増強方法
KR101595063B1 (ko) 세포결합 서열, 헤파린 결합 도메인 및 오스테오칼신 도메인을 포함하는 융합단백질 및 이를 포함하는 약학 조성물
KR100490362B1 (ko) 올리고라이신 수송 도메인, 올리고라이신-화물분자 복합체및 그 용도
KR102274876B1 (ko) 신규한 세포 투과성 펩타이드 및 이의 용도
KR100612673B1 (ko) 세포도입성 보톡신 융합단백질
HUT56881A (en) Process for expressing human nerve growth factor in arthropoda frugiperda cells infected with recombinant baculovirus
JPH11503321A (ja) Ｎｄｆペプチド
DE10054303B4 (de) Analoga, Agonisten, Antagonisten und Varianten der Oxidoreduktase-Enzymaktivität des Makrophagen-Migrations-Inhibitions-Faktors (MIF) als Immunmodulatoren, Therapeutika, Diagnostika und Screening-Agenzien bei inflammatorischen und Immunerkrankungen
EP0535337A2 (en) Cell growth inhibiting activities of heparin binding neurite-outgrowth promoting factor
CA2342970A1 (en) Fusion proteins
CA2113815A1 (en) Purification of recombinant ciliary neurotrophic factor and c-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage
KR20080041037A (ko) 단백질 수송 펩타이드와 짧은 간섭 ｒｎａ와의 복합체 및그 용도
CN115703828A (zh) 一种抗血管生成药物

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090301

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100301

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110301

Year of fee payment: 9

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120301

Year of fee payment: 10